09 Oct 2026, 10:20 IST
Dr. Lal Path Labs Ltd.
HDFC Securities · BUY · target INR 2,220
The report maintains a BUY rating with a revised target price of INR 2,220 (based on 46x Q2FY29E EPS), citing steady volume-led growth, margin stability around 29.2-29.3%, wellness segment traction, and recent M&As in genomics (SN Gene) and international markets (Sunshine Healthcare, Ghana).
From Dr Lal Pathlabs Update Oct 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.